





27 August 2015

Daily news and comments on the Life Sciences Sector in **Australia** by
The Daily Molecule, part of Van Leeuwenhoeck Institute

Companies in Today's newsletter:

- ANTEO DIAGNOSTICS (ASX:ADO)



	27 August 2015	1 mth	3 mth	1yr	YTD
ASX All Ordinaries	5,172.80	-7.2%	-9.5%	-8.3%	-4.4%
Nasdaq Biotech Index	3,582.10	-8.5%	-6.7%	24.5%	11.8%
Nasdaq Index	4,219.60	-6.6%	-7.2%	3.8%	-0.2%
Dow Jones Index	16,285.51	-0.2%	-1.9%	-4.9%	-0.8%
Euro STOXX 50	3,170.73	-6.6%	-10.3%	-0.7%	-8.7%



ANTEO DIAGNOSTICS (ASX:ADO)

PRICE: AUD 0.095 (+4.4%)

Anteo Diagnostics announced that it will acquire DIAsource ImmunoAssays, SA (**DIAsource**), an established global specialty diagnostics company based in Belgium, pursuant to a Share Purchase Agreement. DIAsource is a vertically-integrated specialty diagnostics company that develops, manufactures, markets and distributes clinical diagnostics products in the fields of endocrinology, especially bone metabolism, fertility, cardiovascular and oncology. The Company generated revenue of EUR11.9 million (AUD 18.0 million) in 2014 and EUR 7.2 million (AUD 10.9 million) in the first half of 2015. This represents revenue growth of 25% with an average EBITDA margin of 20.6% this year. DIAsource recently achieved its fifth consecutive revenue growth quarter and fifth consecutive best quarter ever in the company's history, thanks to growth in its Vitamin D portfolio and its established line of specialty RIA and ELISA assays, two different forms of immunoassays. **We feel that this acquisition is a real add on for the company as a whole. Anteo will increase its portfolio of customers and with this acquisition its revenues will increase dramatically, propelling the company into profitability. Based on our NPV valuation, we believe that Anteo Diagnostics is substantially undervalued at the current share price of AUD 0.095. With the acquisition we increase our valuation to AUD 150-180 million, or AUD 0.20-0.25 per share. This represents a substantial upside from the current share price.**

The Daily Molecule is a publication of Van Leeuwenhoeck Institute Inc

Marcel Wijma MSc
CEO & Managing Director

Van Leeuwenhoeck Research (US) Inc
 244 Fifth Avenue, Suite W204
 New York, NY, 10001 USA

Phone US: +1 917 460 6185
 Phone NL: +31 684 892 954

m.wijma@leeuwenhoeck.com
www.leeuwenhoeck.com



Company	Ticker	Price	Perf 1mth	Perf YTD	Perf 1 yr	Market cap
ACRUX	ACR.AX	0.650	-22.7%	-48.2%	-59.8%	108.23
ACTINOGEN	ACW.AX	0.057	-11.4%	-16.2%	244.4%	28.05
ADMEDUS	AHZ.AX	0.070	9.1%	-28.8%	-39.1%	100.98
ANTEO DIAGNOSTICS	ADO.AX	0.095	-9.5%	-20.8%	0.0%	80.26
ANTISENSE	ANP.AX	0.082	-18.2%	0.0%	-35.7%	13.24
AVITA MEDICAL	AVH.AX	0.072	-12.5%	-14.6%	-39.1%	23.42
BENITEC	BLT.AX	0.595	-38.0%	-37.6%	-42.5%	68.78
BIOTRON	BIT.AX	0.100	-11.8%	-7.6%	-20.5%	24.24
BIONOMICS	BNO.AX	0.395	-12.2%	-8.1%	-38.8%	164.91
CIRCADIAN	CIR.AX	0.200	0.0%	21.2%	7.5%	29.62
CYNATA	CYP.AX	0.470	-37.3%	38.2%	28.8%	28.95
CLINUVEL	CUV.AX	2.600	-8.5%	-8.5%	-9.1%	115.96
CELLMID	CDY.AX	0.034	12.9%	34.6%	20.7%	26.96
ELLEX MEDICAL LASERS	ELX.AX	0.340	6.7%	14.3%	-12.3%	36.60
IDT AUSTRALIA	IDT.AX	0.285	21.7%	86.7%	0.0%	54.49
IMPEDIMED	IPD.AX	1.000	31.1%	27.5%	304.2%	293.10
IMUGENE	IMU.AX	0.008	0.0%	10.0%	-21.4%	10.64
INVION GROUP	IVX.AX	0.017	-34.6%	-63.8%	-79.5%	13.99
MESOBLAST	MSB.AX	3.250	-1.2%	-11.1%	-7.5%	1030.58
NEUREN PHARM.	NEU.AX	0.087	12.0%	-31.1%	-7.0%	141.39
NOVOGEN	NRT.AX	0.160	-23.8%	53.8%	7.4%	67.84
ONCOSIL	OSL.AX	0.100	4.5%	33.7%	0.0%	35.53
ORTHOCELL	OCC.AX	0.620	125.0%	71.4%	100.0%	51.15
OSPREY MEDICAL	OSP.AX	0.695	25.8%	41.1%	51.0%	85.62
PHARMAXIS	PXS.AX	0.200	-2.3%	59.3%	241.3%	62.57
PHOSPHAGENICS	POH.AX	0.017	-28.0%	-76.0%	-81.6%	21.45
PHYLOGICA	PYC.AX	0.011	0.0%	-31.6%	8.3%	11.02
PRIMA BIOMED	PRR.AX	0.050	-17.2%	45.5%	14.3%	68.73
PRANA BIOTECH	PBT.AX	0.135	3.2%	-20.0%	-36.0%	66.00
PRESCIENT THERAPEUTICS	PTX.AX	0.069	0.0%	-41.8%	-41.8%	3.64
PSIVIDA	PVA.AX	5.250	11.0%	12.1%	15.6%	154.35
REGENEUS	RGS.AX	0.115	-9.4%	-9.4%	-49.1%	23.07
RESMED	RMD.AX	7.200	8.7%	15.4%	50.7%	10152.00
RHINOMED	RNO.AX	0.039	10.0%	17.9%	-23.3%	21.03
SIMAVITA	SVA.AX	0.480	-4.3%	19.5%	25.0%	44.28
SOMNOMED	SOM.AX	2.455	9.3%	9.3%	74.6%	125.06
STAR PHARMA	SPL.AX	0.575	-11.1%	22.4%	-9.9%	183.48
SUDA	SUD.AX	0.031	6.7%	-45.8%	-36.0%	30.50
TISSUE THERAPIES	TIS.AX	0.054	68.6%	-81.3%	-79.7%	14.22
UNIVERSAL BIOSENSORS	UBI.AX	0.360	35.6%	122.2%	128.6%	63.32
VIRALYTICS	VLA.AX	0.615	-8.5%	154.2%	167.9%	113.16

Source: Van Leeuwenhoeck Institute Inc



Disclaimer

The facts stated and the opinion and prognoses given in this publication are based on data and information considered to be reliable and have been carefully worked into our analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness. Van Leeuwenhoeck Institute. does not accept responsibility or liability in any way in respect to the information stated herein.

Van Leeuwenhoeck Institute does not hold or have positions in securities as referred to in this publication. The views expressed in this publication accurately reflect the analyst's personal views on the subject securities or issuer. Neither the analyst's compensation nor the compensation received by Van Leeuwenhoeck Institute is in any way related to the specific recommendations or views contained in this publication.

Any investments referred to herein may involve significant risk, are not necessarily available in all jurisdictions, may be illiquid and may not be suitable for all investors. The value of, or income from, any investments referred to herein may fluctuate and/or be affected by changes in exchange rates. Past performances are not indicative for future results. Investors should make their own investment decisions without relying on this publication.

Only investors with sufficient knowledge and experience in financial matters to evaluate the merits and risks should consider an investment in any issuer or market discussed herein and other persons should not take any action on the basis of this publication.

Information, opinions or recommendations contained in this publication are submitted solely for advisory and information purposes. The information used and statements of fact made, have been obtained from sources considered reliable, but we neither guarantee nor represent the completeness or accuracy. Such information and the opinions expressed are subject to change without notice. This publication is not intended as an offering or a solicitation of an offer to buy or sell the securities mentioned or discussed.

Van Leeuwenhoeck Institute does not accept any equity compensation. Reports are performed on behalf of the public, and are not a service to any company. The analysts are responsible only to the public, and are paid in advance to eliminate pecuniary interests and insure independence.

Periodic Research reports and research notes on this Company are available at our web site:

www.leeuwenhoeck.com

© Copyright 2015 by Van Leeuwenhoeck Institute Inc.